The Bristol-Myers Squibb Foundation has announced $6 million in additional grants through its Together on Diabetes™ initiative that will help more adults living with type 2 diabetes better manage their disease and make behavioral changes that can improve their overall health.

Abbott (NYSE: ABT) announced results from the Phase 3 ABILITY-2 investigational study of HUMIRA® (adalimumab) in patients with active peripheral spondyloarthritis (PSpA) who have not been diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS).

Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With Background Methotrexate), a head-to-head clinical trial of 646 patients comparing the subcutaneous (SC) formulation of ORENCIA® (abatacept) vs. Humira® (adalimumab),

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint, of a significant improvement in the time patients with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse (progression-free survival; PFS).

The research driven pharmaceutical company Boehringer Ingelheim is establishing a new 50 million-plus euro pilot plant facility for the production of newly developed active pharmaceutical ingredients. The company announced this investment in its largest research and development site worldwide in Biberach, Germany.

UCB (Euronext Brussels: UCB) and Meizler Biopharma, a privately-owned Brazilian pharmaceutical company, have signed an agreement by which UCB acquires 51% of Meizler Biopharma. The agreement foresees performance related milestone payments in the coming years as well as an option to purchase the remaining 49% later in time.

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), marked World MS Day with activities across its global network and new programs designed to mobilize and inspire people living with multiple sclerosis.